Core Viewpoint - A class action has been filed against UroGen Pharma Ltd. due to allegations of improper trial conduct for its lead drug candidate, UGN-102, which is intended to treat low-grade intermediate risk non-muscle invasive bladder cancer [1][2]. Summary by Sections Allegations - Robbins LLP is investigating allegations that UroGen Pharma Ltd. failed to conduct a proper trial for UGN-102, with the rolling new drug application (NDA) submitted on August 14, 2024 [2]. FDA Concerns - On May 16, 2025, the FDA expressed doubts regarding the efficacy data submitted for UGN-102, highlighting that the ENVISION study lacked a concurrent control arm, making the primary endpoints difficult to interpret [3]. - The FDA had previously recommended a randomized trial design multiple times during the product's development, which UroGen did not follow [3]. Stock Price Impact - Following the FDA's concerns, UroGen's stock price dropped by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [3]. - On May 21, 2025, the Oncologic Drugs Advisory Committee voted against the approval of UGN-102, leading to a further decline in stock price by $3.37, or 44.7%, closing at $4.17 per share [4]. Class Action Details - The complaint alleges that UroGen did not disclose critical information regarding the study design and its implications for the NDA approval process, including the lack of a concurrent control arm and the challenges in demonstrating the drug's effectiveness [5]. - Shareholders may be eligible to participate in the class action, with options to serve as lead plaintiff or remain absent class members [6]. Company Background - Robbins LLP has been recognized for its efforts in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [7].

In 2022, Elon Musk unveiled a prototype of Tesla’s humanoid robot Optimus. The Tesla CEO said the robot is expected to cost less than a car. Photo: AFP Photo/Handout/TeslaOne of Tesla’s TSLA 3.67 %increase; green up pointing triangle top artificial-intelligence executives left the company on Friday, a setback for the Optimus robotics project that Chief Executive Elon Musk says is pivotal to the future of the company.Milan Kovac, a vice president of engineering, oversaw Tesla’s development of Optimus, a huma ...

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the proposed sale of Provident Bancorp, Inc. to NB Bancorp, Inc. for Provident shareholders [1][3] Group 1: Transaction Details - Provident shareholders will receive either 0.691 shares of NB Bancorp common stock or $13.00 in cash for each share of Provident common stock [1] - The investigation focuses on whether the board of directors of Provident acted in the best interest of shareholders during the transaction [3] Group 2: Legal Considerations - The investigation questions if Provident and its board violated federal securities laws or breached fiduciary duties by not obtaining the best possible consideration for shareholders [3] - Halper Sadeh LLC may seek increased consideration, additional disclosures, and other benefits for Provident shareholders [4]

NEWTOWN, Pa., June 06, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Humana Inc. (“Humana”) (NYSE: HUM), resulting from allegations of providing potentially misleading business information to the investing public. If you have non-public information that could assist in the Humana investigation, or if you are a Humana investor who suffered a loss and would like to learn more, you can provide your information HERE. You can also con ...

SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Reckitt Benckiser Group PLC (OTC: RBGLY) American Depository Shares (ADSs) between January 13, 2021 and July 28, 2024. Reckitt is a United Kingdom-based global consumer goods company that reports three operating segments: Hygiene, Health, and Nutrition. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at ...

Lululemon lovers are already stretching their wallets to the limit — and now they’ve had enough.Fans and critics alike were clucking their tongues Friday after the athleisure giant warned customers they’d soon be paying even more for already-pricey workout gear — following a whopping stock nosedive.The culprit? President Donald Trump’s tariffs — and, apparently, broke Americans tightening their purse strings.“We experienced lower store traffic in the Americas, partially reflective of economic uncertainty, i ...

Core Insights - Meta's Reality Labs could either achieve significant success or be remembered as a "legendary misadventure" by 2025, with the market being the ultimate judge of its potential [1] - The year 2023 is seen as pivotal for Meta, especially with the successful launch of Ray Ban AI glasses, which have sold over 2 million pairs since their debut in October 2023 [2][4] - Competition is intensifying as other tech giants like Google and Apple are also entering the smart glasses market, with Google partnering with Gentle Monster and Warby Parker, and Apple planning to release its own smart glasses in 2026 [3] Market Dynamics - The market's adoption of Meta's AR and VR products is crucial for driving industry standardization, despite the competition from other incumbents [4] - Meta's CTO emphasizes that the hardware market often lags behind, indicating the importance of early indicators and internal confidence in product execution [7] Execution Focus - The company aims to concentrate on executing its plans rather than being overly concerned with competitors, as many companies fail due to poor execution rather than competition [8] - By the end of 2023, the company will assess whether it has successfully executed its plans, with a longer-term evaluation expected in five years [9]

Company Overview - SelectQuote is a direct-to-consumer insurance platform that offers health, life, auto, and home insurance policies, as well as medication management services through its SelectRx pharmacy division [3] Allegations and Legal Issues - The Department of Justice filed a False Claims Act complaint against SelectQuote on May 1, 2025, alleging the company received millions of dollars in kickbacks from Humana in exchange for specific Medicare Advantage plan enrollments [4] - The complaint claims SelectQuote maintained a sales division that exclusively offered Humana policies and directed a significant portion of its business to Humana [4] Market Reaction - Following the filing of the complaint, SelectQuote's stock price fell by $0.61 per share, or 19.2%, closing at $2.56 per share on May 1, 2025 [5]

Core Viewpoint - Palantir Technologies has transformed from a slow-growth, unprofitable company to a fast-growing, highly profitable business, largely due to the launch of its Artificial Intelligence Platform (AIP) [2] Group 1: Company Performance - Since the start of 2023, Palantir's stock has returned nearly 2,000% [2] - The company now trades at a price-to-sales ratio of 105, indicating significant multiple expansion [3] - Palantir's revenue growth was 39% in its most recent quarter, suggesting strong ongoing performance [10] Group 2: Market Valuation and Predictions - Palantir's market cap has topped $300 billion, making it the most valuable pure-play software company [4] - Analyst Dan Ives predicts Palantir could reach a valuation of $1 trillion in two to three years, raising his price target from $120 to $140 [6][7] - The stock's current valuation presents challenges to achieving the $1 trillion goal, as it would still be considered expensive even with a 75% reduction in price-to-sales valuation [11] Group 3: Government Relations and Growth Drivers - The Trump administration has expanded the federal government's relationship with Palantir, encouraging agencies to share data using its platforms [9] - The scalability of Palantir's subscription software model and its history of expanding operating margins could lead to faster growth on the bottom line [11] - The broader demand for AI and the federal government's embrace of Palantir's services contribute to strong business prospects [12]

Core Insights - Palantir Tech, Inc. (PLTR) experienced a significant trading signal known as Power Inflow at a price of $124.90, indicating a potential uptrend and a possible entry point for traders [1][5]. Group 1: Trading Signals - The Power Inflow is a crucial indicator for traders, reflecting where institutional and "smart money" is moving in the market [1][5]. - This trading signal typically occurs within the first two hours of market open and helps gauge the stock's overall direction for the remainder of the day [3]. Group 2: Order Flow Analytics - Order flow analytics involves analyzing the flow of buy and sell orders, including their size and timing, to make informed trading decisions [2]. - Active traders interpret the Power Inflow as a bullish signal, suggesting a favorable market condition for potential investments [2]. Group 3: Performance Metrics - Following the Power Inflow, Palantir's stock reached a high price of $128.13 and a close price of $127.72, resulting in returns of 2.6% and 2.3% respectively [8].